Antibody therapies direct the immune system to recognise and attack cancer cells, and they have become one of the most promising treatment strategies in paediatric oncology. Yet for children with solid tumours such as neuroblastoma, the antibodies available today remain limited in how effectively and safely they work, leaving a clear need for better ones.
This project develops and screens new antibody constructs designed to target paediatric solid tumours. Using the laboratory’s functional assays, we measure how well each construct engages the immune system to kill tumour cells and identify the strongest candidates for further development. Through this work, we aim to bring forward more effective and better-tolerated antibody therapies for children with these cancers.
The VIVA-Cell and Gene Therapy Academy
Located within VIVA Hub, the VIVA-Cell and Gene Therapy Academy is dedicated to the professional development of healthcare practitioners in the rapidly evolving field of cell and gene therapy.
Equipped with state-of-the-art technologies, the Academy provides specialised training programmes focused on the technical and operational aspects of advanced therapies, including CAR T-cell manufacturing and production processes. Through hands-on learning and knowledge exchange, the Academy seeks to build local and regional capabilities in delivering cutting-edge treatments safely and effectively.
VIVA remains committed to empowering healthcare professionals, advancing innovation in paediatric oncology, and supporting the adoption of transformative therapies that can help children with cancer achieve better health outcomes and improved quality of life.